• Explore /
  • Poster
  • / Fruquintinib with PD-1 inhibitors versus TAS-102 with bevacizumab in late-line mCRC: A retrospective cohort study based on propensity score matching.

Fruquintinib with PD-1 inhibitors versus TAS-102 with bevacizumab in late-line mCRC: A retrospective cohort study based on propensity score matching.

Abstract Poster

Authors

null

Rongrong Li

Department of Medical Oncology Gastroenterology and Urology, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China

Rongrong Li , Xiao-Lin Yang , Zhen-yang Liu , Hui-Jun Zhou , Xian-Li Yin , De-Yu Zeng , Hua Shen , Yi-Dong Zeng , Fang Xiang , Ke Li , Shao-Feng Jiang , Wu Liu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 95)

DOI

10.1200/JCO.2024.42.3_suppl.95

Abstract #

95

Poster Bd #

F18

Abstract Disclosures

Similar Posters

First Author: Tianqi An

First Author: Linlin Xu

Poster

2022 ASCO Gastrointestinal Cancers Symposium

Effect of fruquintinib on programmed death receptor-1 blockade antitumor immune responses in colorectal cancer.

Effect of fruquintinib on programmed death receptor-1 blockade antitumor immune responses in colorectal cancer.

First Author: Qingli Li

First Author: Elena Fountzilas